The Cancer and Blood Diseases Institute at Cincinnati Children’s is a national leader in caring for children and adolescents with cancer. The institute's cancer program was rated among the best in the nation for 2016-17 by U.S. News & World Report. Our experienced physicians offer the most advanced therapies for patients who are newly diagnosed, and those seeking innovative treatments for rare, relapsed and recurrent cancers. These physicians possess the expertise and resources to care for those patients with very challenging conditions that other pediatric hospitals may consider too difficult to treat.
At Cincinnati Children’s, our cancer doctors are not generalists. Rather, they specialize in treating specific cancers, developing a deep understanding of the disease and treatment options that offer the most promise.
Areas of specialty include:
Our physicians work closely with nurses, social workers and other members of the care team to provide early, accurate diagnoses, appropriate medical treatment, family support and patient education. The team strives to help patients maintain a “normal” life by helping them keep up in school and providing treatment on an outpatient (rather than inpatient) basis whenever possible.
The director of the Division of Oncology is
John Perentesis, MD, a nationally recognized expert in the development of anticancer drugs for children and young adults. His leadership roles include the National Cancer Institute's Investigational Drug Steering Committee, the Neurofibromatosis Consortium Drug Development and Executive Committees, the Myeloid Leukemia Relapse Committee and the Adolescent / Young Adult Cancer Committee of the Children's Oncology Group.
Dr. Perentesis and Oncology Division faculty are developing effective treatment approaches for high-risk and relapsed childhood cancers and leukemia and innovative approaches to care for adolescents and young adults.
The Oncology Division is a national referral center for specialized leading-edge care of children and young adults with cancer and leukemia and for multidisciplinary long-term follow-up of cancer survivors.